Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

20093,394 citationsJournal Articlebronze Open Access

Authors

Steven R. Cummings · California Pacific Medical Center

Javier San Martín · Amgen (United States)

Michael R. McClung · Bone Health and Osteoporosis Foundation

Ethel S. Siris · Columbia University Irving Medical Center

Richard Eastell · University of Sheffield

Ian R. Reid · University of Auckland

Pierre Delmas

Abstract

Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)

Topics & Keywords

Bone Metabolism and Diseases Bone health and treatments Bone health and osteoporosis research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 8, pp. 756-765

DOI: 10.1056/nejmoa0809493

Field-Weighted Citation Impact: 86.01